SBIR-involved in its early years but not for some time since then, Advaxis, Inc. (NASDAQ:ADXS) is a biotechnology company utilizing two immunological mechanisms (Innate and Classical Immunity) to develop more effective and safe cancer vaccines. In mid-Jamuary 2023, it was announced that cancer treatment developers Ayala Pharmaceuticals and Advaxis had completed merger of the two firms. Advaxis had been the exclusive licensee of a broadly enabling platform technology for creating cancer vaccines that utilize innate immune system which consists of immune cells, including dentritic cells, macrophages and natural killer cells. The Dendritic cells and macrophages will respond to the pathogens nonspecifically by releasing chemical messengers, cytokines and chemokines that recruit other defensive elements of the immune system. Thus when innate immunity is combined with the classical (adaptive) antibody and cellular immune mechanisms, they can elicit more effective anti-tumor responses. The combination of the innate immunity platform with classical adaptive immuniemechanisms will also have applications in the fields of infectious disease and autoimmune disorders ||||||| In early July 2021, it was announced that ADXS Stock had increased by more that 30%: Why It Happened: Investors were responding positively to Advaxis and Biosight a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders announcing that the two firms companies had entered a definitive merger agreement whereby Biosight shareholders become the majority holders of the combined company immediately following completion of the transaction. Proposed merger creates a public company prioritieing the clinical advancement and commercialization of Biosights lead product aspacytarabine (BST-236). The combined company reproted as having c. $50 million in cash, cash equivalents, and marketable securities at closing. Advaxis renamed Biosight Therapeutics and expected to trade on Nasdaq with ticker symbol BSTX.
